Comparative Pharmacology
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus ATONCY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus ATONCY.
ATOMOXETINE HYDROCHLORIDE vs ATONCY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective norepinephrine reuptake inhibitor (NRI) that increases noradrenergic neurotransmission in the prefrontal cortex.
Atoncy (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby blocking downstream signaling pathways involved in cell proliferation and survival.
Initial 40 mg orally once daily; increase after minimum 3 days to 80 mg/day; maximum 100 mg/day if inadequate response after 2-4 weeks.
ATONCY (crizotinib) 250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in CYP2D6 extensive metabolizers; in poor metabolizers, half-life is prolonged to about 21-24 hours.
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in patients with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal: approximately 80% of a dose is excreted in urine, with 2-3% as unchanged drug; 17% fecal.
Primarily renal excretion as unchanged drug (approximately 70%) and as metabolites (approximately 20%); biliary/fecal excretion accounts for the remaining 10%.
Category C
Category C
Norepinephrine Reuptake Inhibitor
Norepinephrine Reuptake Inhibitor